Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Melphalan
Drug ID BADD_D01376
Description An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - melphalan, the racemic mixture - merphalan, and the dextro isomer - medphalan; toxic to bone marrow, but little vesicant action; potential carcinogen.
Indications and Usage For the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary. Has also been used alone or as part of various chemotherapeutic regimens as an adjunct to surgery in the treatment of breast cancer, alone or in combination regimens for palliative treatment of locally recurrent or unresectable in-transit metastatic melanoma of the extremities, as well as for the treatment of amyloidosis with prednisone.
Marketing Status approved
ATC Code L01AA03
DrugBank ID DB01042
KEGG ID D00369
MeSH ID D008558
PubChem ID 460612
TTD Drug ID D00FGO
NDC Product Code 71052-158; 50683-0385; 76055-0021; 68554-0076; 72893-001
UNII Q41OR9510P
Synonyms Melphalan | L-PAM | Phenylalanine Mustard | Mustard, Phenylalanine | 4-(Bis(2-chloroethyl)amino)phenylalanine | Medphalan | Sarkolysin | Sarcolysine | Merphalan | Alkeran
Chemical Information
Molecular Formula C13H18Cl2N2O2
CAS Registry Number 148-82-3
SMILES C1=CC(=CC=C1CC(C(=O)O)N)N(CCCl)CCCl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gait disturbance08.01.02.002; 15.03.05.013; 17.02.05.0160.000112%
Gastrointestinal disorder07.11.01.0010.000168%-
Generalised tonic-clonic seizure17.12.01.0020.000168%-
Haemoglobin13.01.05.018---
Haemolytic anaemia01.06.03.002---
Hepatic failure09.01.03.0020.000168%
Hepatitis09.01.07.004---
Hepatocellular injury09.01.07.008---
Hepatotoxicity09.01.07.009; 12.03.01.0080.000224%-
Hiccups07.01.06.009; 22.12.01.0010.000336%
Hyperglycaemia05.06.02.002; 14.06.02.0020.000280%
Hyperkalaemia14.05.03.0010.000168%
Hypermagnesaemia14.04.02.0020.000280%
Hypernatraemia14.05.04.0010.000112%
Hypersensitivity10.01.03.003--
Hypertension24.08.02.0010.000168%
Hypertonic bladder17.10.01.003; 20.03.03.003---
Hypertriglyceridaemia14.08.02.0010.000112%
Hyperuricaemia14.09.01.0030.000783%
Hypoalbuminaemia09.01.02.003; 14.10.01.0020.000728%
Hypocalcaemia14.04.01.0040.000504%
Hypoglycaemia05.06.03.001; 14.06.03.0010.000280%
Hypokalaemia14.05.03.0020.000280%
Hypomagnesaemia14.04.02.0010.000672%
Hyponatraemia14.05.04.0020.000672%
Hypophosphataemia14.04.03.0010.000560%
Hypotension24.06.03.0020.000504%
Hypotony of eye06.08.03.0040.000280%-
Hypoxia22.02.02.0030.000112%
Immune system disorder10.02.01.0010.000168%-
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 8 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene